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The fibroblast growth factor receptor (FGFR) family
of receptor tyrosine kinases has been implicated in
a wide variety of cancers. Despite a high level of
sequence homology in the ATP-binding site, the ma-
jority of reported inhibitors are selective for the
FGFR1-3 isoforms and display much reduced po-
tency toward FGFR4, an exception being the Bcr-
Abl inhibitor ponatinib. Here we present the crystal
structure of the FGFR4 kinase domain and show
that both FGFR1 and FGFR4 kinase domains in
complex with ponatinib adopt a DFG-out activation
loop conformation. Comparison with the structure
of FGFR1 in complex with the candidate drug
AZD4547, combined with kinetic characterization of
the binding of ponatinib and AZD4547 to FGFR1
and FGFR4, sheds light on the observed differences
in selectivity profiles and provides a rationale for
developing FGFR4-selective inhibitors.
INTRODUCTION
The fibroblast growth factor (FGF)-FGF receptor (FGFR)
signaling system plays important roles in development and tis-
sue repair through the initiation of multiple signaling cascades
controlling proliferation, differentiation, migration, and survival
(Brooks et al., 2012; Turner and Grose, 2010). Dysregulation of
this signaling axis has been shown to play a critical role in tumor
development and progression. Activating mutations in members
of the FGFR tyrosine kinase family (FGFR1, FGFR2, FGFR3, and
FGFR4) are emerging as significant markers of a number of hu-
man cancers and other diseases (Greulich and Pollock, 2011).
FGFR4 is activated by the binding of the extracellular growth
factors FGF1 and FGF19 to the extracellular domains of the
transmembrane receptor, an event that results in receptor
dimerization. Upon receptor dimerization, the intracellular tyro-
sine kinase domains undergo autophosphorylation, resulting in1764 Structure 22, 1764–1774, December 2, 2014 ª2014 Elsevier Ltdfurther activation of basal tyrosine kinase activity, leading to
phosphorylation and activation of its intracellular substrates
(FGFR substrate 2a and phospholipase Cg1) and initiation of
downstream signaling pathways (RAS-MAPK, PI3K-AKT, and
PKC) (Goetz and Mohammadi, 2013). In addition, FGFR4 can
activate other signaling molecules, including signal transduction
and activation of transcription (Hart et al., 2000). The FGFR4-
FGF19 complex is further stabilized by binding of the tissue-spe-
cific coreceptor b-Klotho (Kurosu et al., 2007; Lin et al., 2007;Wu
et al., 2010). Overexpression of FGFR4, FGF1, and FGF19 and
activatingmutations in FGFR4 (e.g., Gly388Arg) have been asso-
ciated with poor prognosis in a wide variety of tumor types, such
as breast, colon, and lung adenocarcinomas (Bange et al., 2002;
Spinola et al., 2005a, 2005b; Thussbas et al., 2006); hepatocel-
lular carcinoma (Ho et al., 2009; reviewed inMellor, 2014); serous
ovarian cancer (Birrer et al., 2007; Zaid et al., 2013); rhabdomyo-
sarcoma (RMS) (Taylor et al., 2009), and pancreatic (Chen et al.,
2010a), colorectal, and gastric cancers (Jang et al., 2001; Ye
et al., 2011). A number of germline and somatic mutations in
FGFR4 identified in tumor samples have been shown to both
increase FGFR4 signaling and drive cell proliferation in model
systems, further supporting the role of FGFR4 in oncogenic pro-
gression (Roidl et al., 2010; Ruhe et al., 2007; Taylor et al., 2009).
The potential of targeting FGFR4 as a therapeutic intervention
is supported by promising data for a number of biopharmaceu-
tical agents targeting the FGF19-FGFR4 interaction. An anti-
FGFR4 monoclonal antibody (LD1) that inhibits binding of FGF
ligands (FGF19 and FGF1) to FGFR4 has been shown to inhibit
proliferation in vitro and in preclinical models of liver cancer
(French et al., 2012). Inhibition of FGF19-FGFR4 signaling in co-
lon cancer using an alternative FGF19-blocking antibody (IA6)
has been shown to inhibit the growth of HCT116 and Colo201
xenograft tumors (Desnoyers et al., 2008). In a repeat-dose
safety study in cynomolgus monkeys, however, anti-FGF19
treatment exhibited dose-related liver toxicity (Pai et al., 2012).
FGFR4 function is not essential during embryogenesis or adult
life inmice (Weinstein et al., 1998), suggestive of a favorable ther-
apeutic margin. FGFR4 function is, however, required for the
correct regulation of bile acid synthesis via Cyp7A1, and inhi-
bition of FGFR4 has been shown to result in bile acid malab-
sorption (reviewed in Mellor, 2014). A recent study using bothAll rights reserved
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Structures of FGFR1 and FGFR4 Inhibitor ComplexesFGFR4-targeted small interfering RNA and the small-molecule
pan-FGFR kinase inhibitor BGJ398 indicated that FGFR4 is a
targetable regulator of chemoresistance in advanced colorectal
cancer and that inhibition of FGFR4 in combination with the anti-
metabolite 5-fluorouracil and the DNA-damaging agent oxalipla-
tinmay present a potential therapeutic strategy for this indication
(Turkington et al., 2014). Further dissection of the role of FGFR4
kinase activity in normal and aberrant physiological processes
and its relevance as a therapeutic target is hampered by the
lack of FGFR4-selective small-molecule kinase inhibitors. Devel-
opment of such inhibitors would, in turn, be assisted by the avail-
ability of structural information on the kinase domain of FGFR4.
Structures of the kinase domains of FGFR1 (Mohammadi et al.,
1996), FGFR2 (Chen et al., 2007), and FGFR3 (Huang et al.,
2013) have been described, but until now, that of FGFR4 has
not been reported.
The majority of reported small-molecule FGFR inhibitors for
which in vitro pan-isoform selectivity data are available display
much reduced potency toward FGFR4 compared to FGFR1-3
(Ho et al., 2014). The pyrazole derivative AZD4547, a selective in-
hibitor of FGFR tyrosine kinases currently in phase II clinical trials
(ClinicalTrials.gov identifier NCT01457846) for the treatment of
FGFR-dependent tumors, shows single-digit nanomolar inhibi-
tion of FGFR1-3 in an enzyme assay. Its half maximal inhibitory
concentration (IC50) for isolated FGFR4, however, is markedly
reduced (1,000-fold) (Gavine et al., 2012). In contrast, the multi-
targeted tyrosine kinase inhibitor (TKI) ponatinib (AP24534),
which has been shown to bind the ‘‘DFG-out’’ conformation of
Bcr-Abl (Zhou et al., 2011), shows potent pan-FGFR activity
(Gozgit et al., 2012). In the DFG-out conformation, the Phe side
chain (the F of the DFG motif) is flipped out of its hydrophobic
pocket, and targeting of this pocket adjacent to the ATP-binding
site is characteristic for type II inhibitors. In contrast, type I inhib-
itors bind competitively with ATP and do not require a flip of the
DFGmotif for binding (Norman et al., 2012b; Liu and Gray, 2006).
To date, all reported FGFR-inhibitor complex structures show
binding to a ‘‘DFG-in’’ conformation of the kinase domain in
which the Phe side chain is in a conformation compatible with
ATP binding.
The conformation of the DFG motif is one defining feature
of the active versus inactive state. Additional features of active
kinase structures include the so-called hydrophobic spine, com-
prising four highly conserved hydrophobic residues (Leu536,
Met524, His610, and Phe631 in FGFR4) (Kornev et al., 2006).
In the active state, interactions between these residues link the
gatekeeper residue (Liu et al., 1998) (Val550 in FGFR4) to the
phosphorylated tyrosine (Tyr643 in FGFR4) of the activation
loop. The gatekeeper residue lies at the beginning of the hinge
region linking the N- and C-terminal lobes of the kinase domain.
Activating mutations in the gatekeeper residue of SRC, EGFR,
and Abl kinases have been proposed to stabilize the hydropho-
bic spine through improved packing (Azam et al., 2008). In addi-
tion, FGFR kinase activity is controlled by a network of hydrogen
bonds between conserved residues (Glu551, Asn535, and
Lys627 in FGFR4) in the vicinity of the hinge region termed the
‘‘molecular brake’’ (Chen et al., 2007). This network restricts
the interlobe closure required for the productive alignment of
catalytic residues. Disease-associated mutations of key resi-
dues in this network have been described in all FGFR isoforms,Structure 22, 1764–17including FGFR4 (reviewed in Greulich and Pollock, 2011). These
mutations lead to inappropriate activation of FGFR kinase activ-
ity mediated through disengagement of the ‘‘brake’’ (Chen et al.,
2007). Activating mutations in the gatekeeper and molecular
brake residues have also been associated with chemoresistance
in a number of kinases, including FGFRs (Byron et al., 2013;
O’Hare et al., 2007).
In an attempt to understand isoform- and inhibitor-dependent
differences at a molecular level, we have solved the structures of
FGFR4 in complex with ponatinib and of FGFR1 in complex with
both AZD4547 and ponatinib. Here we reveal that FGFR, in com-
monwith a diverse subset of kinases, including p38 (Protein Data
Bank [PDB] accession number 1KV2), cAbl (PDBaccession num-
ber 1OPJ), Aurora kinase (PDB accession number 2C6E), CDK8
(‘‘DMG-out’’; PDB accession number 3RGF), and MNK (‘‘DFD-
out’’; PDB accession number 2AC3), can adopt a DFG-out
activation loop conformation. Comparisons of the AZD4547
and ponatinib binding modes and accompanying binding ki-
netics determined using surface plasmon resonance (SPR)
provide insight into the molecular determinants governing inhib-
itor-dependent potency differences toward FGFR1 and FGFR4
kinases. We discuss the implications of our findings for the
design of FGFR4 isoform-selective TKIs.
RESULTS
The Structure of FGFR4 in Complex with Ponatinib
Reveals a DFG-Out Binding Mode
In order to understand the molecular basis by which FGFR4-se-
lective inhibitors may be developed, we began by determining
the crystal structure of the kinase domain of FGFR4. We de-
signed a series of constructs encompassing the kinase domain
of FGFR4, including both wild-type sequences and also incorpo-
rating a Cys477Ala mutation in the glycine-rich loop by analogy
with the construct used to obtain crystals of FGFR1 (Moham-
madi et al., 1996). Purified FGFR4 showed heterogeneous phos-
phorylation at up to four sites, and no crystals were obtained
from this sample. In order to improve sample homogeneity, we
coexpressed FGFR4 with PTP1B to generate nonphosphory-
lated FGFR4. In the absence of ligand, FGFR4 failed to crystallize
despite extensive screening, we therefore used differential scan-
ning fluorimetry to assess the effect of a variety of potential
FGFR4 ligands on the protein melting temperature (Tm) in order
to identify conditions more likely to result in crystal formation
(Niesen et al., 2007). Both Cys477Ala and wild-type, phosphory-
lated, and nonphosphorylated FGFR4 showed significant sta-
bilization (monitored as an increase in Tm) in the presence of a
variety of FGFR inhibitor chemotypes (Table S1 available online;
data not shown). The largest stabilization (+11.1 ± 0.4 K) was
observed in the presence of the multitargeted TKI ponatinib,
and diffraction quality crystals were obtained for the complex
of nonphosphorylated FGFR4 (Ala447-Glu753 [Cys477Ala])
with ponatinib. Compounds showing lower Tm shifts failed to
yield diffraction quality crystals. Data were collected from
several crystals of the FGFR4-ponatinib complex harvested
from the initial screening condition and showed variable dif-
fraction quality. In order to maximize the data resolution and
completeness, data from three crystals were combined to give
an overall resolution limit of 1.85 A˚ (Table 1; Experimental74, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1765
Table 1. Crystallographic Data Collection and Refinement Statistics
Protein
FGFR1 (458–765)
[C488A C584S]
FGFR1 (458–765)
[C488A C584S]
FGFR1 (458–765)
[C488A C584S]
FGFR4 (447–753)
[C477A]
Ligand ponatinib ponatinib AZD4547 ponatinib
PDB accession number 4V01 4V04 4V05 4UXQ
Ligand introduction method soak cocrystallization soak cocrystallization
X-ray source Rigaku FRE rotating
anode
Rigaku FRE rotating
anode
Rigaku FRE rotating
anode
Diamond i04-1 and
ESRF ID29
Wavelength (A˚) 1.54 1.54 1.54 0.89 and 0.92
Space group C2 C2 C2 P21
Cell constants a; b; c (A˚) 207.2; 58.1; 65.2
b = 107.4
206.8; 57.5; 65.6
b = 107.5
208.8; 57.5; 65.6
b = 107.6
41.8; 58.4; 60.6 b = 96.5
Resolution range (A˚)a 98.89–2.33 (2.45–2.33) 98.62–2.12 (2.29–2.12) 99.48–2.57 (2.71–2.57) 60.18–1.85 (1.95-1.85)f
Completeness overall (%)a 94.2 (83.7) 97.7 (90.1) 96.8 (97.1) 56.9 (8)e
Reflections, unique 30,021 41,149 22,994 14,141
Multiplicitya 2.3 (2.3) 3.5 (2.7) 3.7 (3.8) 4.6 (2.6)
Mean (I)/SD (I)a 18.2 (5) 21.5 (3.1) 15.2 (2.7) 7.3 (2.6)
Rmerge overall
a,b 0.033 (0.20) 0.042 (0.379) 0.057 (0.458) 0.18 (0.287)
Rvalue overall (%)
c 19.6 18.81 19.55 20.14
Rvalue free (%)
c 24.4 22.80 25.56 26.81
Nonhydrogen protein atoms 4308 4594 4439 2241
Nonhydrogen ligand atoms 78 78 68 39
Solvent molecules 277 420 143 229
Rmsd values from ideal values
Bond length (A˚) 0.007 0.010 0.010 0.010
Bond angle () 1.19 1.05 1.12 1.12
Average B values (A˚2)
Protein main-chain atoms 28.7 47.7 54.1 21.1
Protein all atoms 29.4 49.9 55.9 23.7
Ligand 30.2 38.4 52.0 17.3
Solvent 42.8 57.5 50.5 27.2
F, J angle distribution for residuesd
In most favored regions (%) 93.2 92.6 93.5 91.3
In additional allowed regions (%) 6.4 6.8 6.0 8.3
In generously regions (%) 0.4 0.6 0.4 0.4
In disallowed regions (%) 0.0 0.0 0.0 0.0
aValues in parentheses refer to the outer resolution shell.
bRmerge = Shkl[(SijIi  <I>j)/SiIi].
cRvalue = ShkljjFobsj  jFcalcjj/ShkljFobsj. Rvalue free is the cross-validation R factor computed for the test set of 5% of unique reflections.
dRamachandran statistics as defined by PROCHECK (Laskowski et al., 1993).
eOverall completeness to 2.4 A˚ is 90% and to 2.2 A˚ is 84%.
fData collection and processing statistics are given for the merged data set, combining data from three individual crystals.
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Structures of FGFR1 and FGFR4 Inhibitor ComplexesProcedures). The structure was solved by molecular replace-
ment, initially using a low-resolution structure of FGFR4 and
subsequently using a high-resolution structure of FGFR1 (Sup-
plemental Experimental Procedures).
The refined model consists of residues Leu452 to Val750, the
inhibitor and 229water molecules (see Table 1 for detailed statis-
tics of the refinement and final model quality). FGFR4 exhibits the
canonical two-domain architecture of protein kinases; a smaller
N-terminal domain comprising a five-stranded b sheet and the
aC-helix and a larger, predominantly a helical C-terminal domain
(Figure 1A).1766 Structure 22, 1764–1774, December 2, 2014 ª2014 Elsevier LtdThe structure of the FGFR4 kinase domain is highly homolo-
gous to that of other FGFR family members, with root-mean-
square deviation (rmsd) values of 1.06, 1.31, and 1.41 A˚ over
the aC’s of the 266, 268, and 263 corresponding residues in
FGFR1 (PDB accession number 1FGK), FGFR2 (PDB accession
number 2PSQ), and FGFR3 (PDB accession number 4K33),
which show sequence identities of 74%, 75%, and 77%, respec-
tively. The entire activation loop, comprising residues Ile628
to Pro652, is ordered including the tyrosine residues Tyr642
and Tyr643, which become phosphorylated upon activation. It
should be noted that the ordered activation loop in FGFR4 packsAll rights reserved
Figure 1. Crystal Structure of the Catalytic
Domain of FGFR4 Kinase in Complex with
Ponatinib
(A) Ribbon representation of the X-ray crystal
structure of FGFR4 in complex with ponatinib (car-
bon atoms in green, van der Waals surface repre-
sentation also shown). The termini are denoted by
N and C; b strands and a helices are labeled and
numbered. The hinge region (yellow), P loop (blue),
and activation loop (orange) are highlighted.
(B) 2D chemical representation of ponatinib, which
is composed of several motifs designated as the
(imidazopyridazine) template, the (methylphenyl) A
ring and (trifluoromethylphenyl) B ring, as well as
the two linkers (Zhou et al., 2011).
(C) Active site of FGFR4 kinase in complex with
ponatinib (carbon atoms in green) as determined at
1.85 A˚ resolution. Fo – Fc OMIT electron density
map for ponatinib and the DFG motif is repre-
sented as a blue mesh contoured at 3.0s. Polar
interactions are indicated as dotted lines. Selected
residues are represented as sticks and labeled.
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Structures of FGFR1 and FGFR4 Inhibitor Complexesagainst a symmetry-related molecule making extensive con-
tacts. A loop-turn-helix motif formed by residues 704 to 728
(from the linker connecting helices aG and aH and helix aH) of
the symmetry-related molecule packs against the C-terminal
lobe, masking from solvent a hydrophobic surface patch formed
by residues Leu661, Phe662, and Phe669. The side chain of
Asp709 from the symmetry-related molecule makes specific
crystal contacts with the main chain amides of Val637 and
His638.
Ponatinib (Figure 1B) can be unambiguously modeled in the
electron density map (Figure 1C) and occupies the cleft be-
tween the N- and C-terminal lobes where ATP would otherwise
bind. The interactions between ponatinib and FGFR4 are similar
to those seen in the complex between ponatinib and the Bcr-Abl
Thr315Ile mutant (PDB accession number 3IK3) (O’Hare et al.,
2009; Zhou et al., 2011). The imidazopyridazine template (see
Figure 1B for nomenclature) forms a hydrogen bond to the
backbone nitrogen atom of Ala553 located in the hinge, while
the methylphenyl A ring occupies the hydrophobic pocket
located behind the gatekeeper residue, Val550. Critical to the
binding of ponatinib is a conformational rearrangement of the
conserved Asp630-Phe631-Gly632 (DFG) tripeptide motif at
the proximal end of the activation loop. In the complex of pona-
tinib with FGFR4, the side chain of Phe631 is flipped out toward
the solvent, thereby creating an induced-fit hydrophobic pocket
into which the trifluoromethylphenyl B ring binds. This observa-
tion of the DFG-out activation loop conformation in the FGFR ki-
nase family confirms ponatinib as a type II FGFR inhibitor. The
amide connecting the A and B rings (linker 2) is involved in a
pair of hydrogen bond interactions with the backbone nitrogen
atom of Asp630 from the DFG motif and the side chain of the
strictly conserved glutamate of the aC-helix (Glu520), which is
characteristic of a type II inhibitor (Liu and Gray, 2006). The
distance between the terminal piperazinyl nitrogen atom of po-
natinib and the carbonyl oxygen atom of residue Ile609 in the
catalytic loop is 3.0A˚, suggesting that the piperazinyl nitrogen
atom is protonated such that the tertiary ammonium ion forms
a hydrogen bond.Structure 22, 1764–17The Structure of FGFR1 in Complex with Ponatinib
Confirms the Propensity of FGFRs to Adopt a DFG-Out
Binding Mode
In order to ascertain whether the DFG-out activation loop con-
formation is more generally accessible to FGFR kinases, we
generated structures of the FGFR1 kinase domain in complex
with ponatinib. We chose to work with FGFR1 because this sys-
tem has been extensively characterized by us, from both struc-
tural and biophysical perspectives (Klein et al., 2014; Norman
et al., 2012a). Structures of a crystallizable form of the FGFR1 ki-
nase domain (Ala458 to Glu765 [Cys488A Cys584S]) in complex
with ponatinib were generated using both cocrystallization and
crystal-soaking protocols (Table 1; Supplemental Experimental
Procedures). In both structures, there are two molecules of
FGFR1 in the crystallographic asymmetric unit related by a non-
crystallographic two-fold axis. The refinedmodels consist of res-
idues Leu465 to Glu765 of monomer A and Ser461 to Asn763 of
monomer B. The two monomers are highly similar, exhibiting
rmsd values of 0.38 A˚ over 269 Ca and 0.41 A˚ over 281 Ca for
the soaked and cocrystallized structures, respectively. The two
structures are also essentially identical (rmsd values of 0.29 A˚
over 273 Ca of monomers A and 0.31 A˚ over 275 Ca of mono-
mers B). Interestingly, however, ponatinib is present at 55%
occupancy in the FGFR1 cocrystal structure such that both
DFG-in and DFG-out conformations of the activation loop can
be visualized simultaneously. In contrast, the DFG-out confor-
mation is observed at 100% occupancy in the FGFR1 structure,
which was obtained by soaking of ponatinib, suggesting that this
crystal form is compatible with the protein movements required
to achieve the DFG-in/DFG-out flip. Further discussionwill there-
fore refer tomonomer A from the higher occupancy structure ob-
tained by soaking ponatinib, except where specifically indicated
otherwise.
In contrast to the structure of FGFR4 in complex with ponati-
nib, the activation loop and the P loop of the FGFR1-ponatinib
complex structure are only partially resolved in the electron den-
sity map. P loop residues Glu486 to Phe489 of monomer A and
Ala488 to Phe489 of monomer B and activation loop residues74, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1767
Figure 2. Crystal Structure of the Catalytic
Domain of FGFR1 Kinase in Complex with
Ponatinib
(A) Ribbon representation of the X-ray crystal
structure of FGFR1 in complex with ponatinib
(carbon atoms in gray, van der Waals surface
representation also shown) obtained by soaking,
labeled and colored as in Figure 1A.
(B) Active site of FGFR1 kinase in complex with
ponatinib (carbon atoms in gray) as determined at
2.33 A˚ resolution. Fo – Fc OMIT electron density
and polar interactions are represented as in Fig-
ure 1C.
(C) Overlay of the active sites of FGFR1 kinase
(gray ribbon representation) and FGFR4 kinase
(dark green ribbon representation) in complex with
ponatinib (carbon atoms in gray and green
respectively).
In (B) and (C), selected residues are shown as
sticks and labeled.
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Structures of FGFR1 and FGFR4 Inhibitor ComplexesGly643 to His650 frommonomers A and B could not be modeled
(Figure 2A). The features that result in the FGFR4 activation
loop being ordered are not conserved in the FGFR1 crystal sys-
tem. Ponatinib can be unambiguously modeled in the electron
density map (Figure 2B) and, as observed for the FGFR4-pona-
tinib complex, binds in a type II binding mode to FGFR1 making
identical interactions to those observed for FGFR4 (Figure 2C).
The Structure of FGFR1 in Complex with AZD4547
Exemplifies a Type I Inhibitor Binding Mode and Is
Accompanied by P Loop Closure
AZD4547 is a potent and selective inhibitor of FGFR1, FGFR2,
and FGFR3 currently in clinical trials for a variety of FGFR-driven
tumors (ClinicalTrials.gov identifier NCT01457846). AZD4547 is
approximately 1,000-fold more potent against FGFR1 than
FGFR4 in an enzyme assay and 10-fold less potent against
FGFR4 than ponatinib (see Table 2). In an attempt to rationalize
these dramatic differences in FGFR isoform selectivity between
ponatinib and AZD4547, we generated the structure of FGFR1 in
complex with AZD4547 (Figure 3A) by soaking the compound
into preformed crystals of the FGFR1 kinase domain. As
observed for the FGFR1-ponatinib complex structure, there are
two molecules of FGFR1 in the crystallographic asymmetric
unit. The refined model consists of residues Glu464 to Glu765
of monomer A and Gly459 to Gln764 of monomer B (see Table
1 for details of crystallographic data collection and refinement
statistics). The two monomers are highly similar, exhibiting
rmsd values of 0.82 A˚ over 281 Ca and 0.26 A˚ over 25 Ca within
4.5 A˚ of the AZD4547 binding site. Further discussion will there-
fore refer to the structure of monomer A, except where specif-
ically indicated otherwise.
AZD4547 (Figure 3B) occupies the ATP-binding cleft of
FGFR1, as expected on the basis of previous structures of
FGFR1 in complex with other pyrazole series inhibitors (Klein
et al., 2014; Norman et al., 2012a) (PDB accession numbers
4F63, 4F64, 4F65, 4NK9, 4NKA, and 4NKS), and the activation
loop in the FGFR1-AZD4547 complex structure exhibits a
DFG-in conformation. The activation loop is only partially or-1768 Structure 22, 1764–1774, December 2, 2014 ª2014 Elsevier Ltddered (residues Asp647 to His650 of monomer A and Ala645
to Ile648 of monomer B could not be modeled), but the con-
formation of the DFGmotif is clearly defined (Figure 3C). The pyr-
azole amide template forms three hydrogen bonds to the hinge
region, while the dimethoxyphenyl A ring occupies the hydro-
phobic pocket located behind the gatekeeper residue (Val561).
One of the methoxy oxygen atoms is involved in a hydrogen
bond with the backbone nitrogen atom of the DFG aspartate
(Asp641), mimicking the A ring and linker 1 amide interactions
of ponatinib (Figure 3D). As observed for other compounds of
the pyrazole series (PDB accession numbers 4F65, 4NK9, and
4NKS) and the potent inhibitor PD173074 (PDB accession num-
ber 2FGI), AZD4547 binds to FGFR1 with the plane of the 3,5-di-
methoxyphenyl ring approximately perpendicular to the plane of
the template. The dimethylpiperazinylphenyl solubilizing group
extends away from the hinge region toward the solvent channel
and does notmake any specific interactions with the protein. The
P loop is well ordered in both monomers and, as previously re-
ported (Klein et al., 2014; Simard et al., 2010), adopts a ‘‘closed’’
conformation (Figure 3B) that shields the ligand from the sur-
rounding solvent. The side chain of Phe489 from the tip of the
P loop stacks against the dimethoxyphenyl A-ring in a parallel
displaced conformation and occupies a constricted indentation
at the base of the ATP-binding pocket (residues Asn628,
Leu630, and Ala640), which was previously referred to as the
‘‘pit’’ region (Norman et al., 2012a). Interestingly, in complexes
with those compounds of the pyrazole series which contain a
methyl isoxazole moiety, this latter moiety is also observed to
occupy the FGFR1 pit region (PDB accession numbers 4F64,
4F65, 4NK9, 4NKA, and 4NKS).
Structural and Biophysical Comparison of FGFR1 and
FGFR4 with Bound Ponatinib and AZD4547 Sheds Light
on Isoform Selectivity Differences
There are two differences in sequence between FGFR isoforms 1
to 3 and FGFR4 in the vicinity of the AZD4547 and ponatinib
binding sites. Residue Leu494, located at the C-terminal end of
the P loop in FGFR1, is a methionine in FGFR2 (Met497) andAll rights reserved
Table 2. Binding Kinetic and Biochemical Inhibition Data for
Ponatinib and AZD4547 toward FGFR1 and FGFR4 Kinase
Domains
AZD4547 Ponatinib
FGFR1
kon (M
1 s1) 2.5 3 107 ± 3.2 3 105a 2.4 3 104 ± 1.4 3 101
koff (s
1) 6.0 3 103 ± 1.2 3 104 1.8 3 104 ± 7.7 3 108
KD (nM) 0.2 ± 0.01 7.7 ± 0.03
pIC50 9.7 8.9 (8.7)
FGFR4
kon (M
1 s1) R1.0 3 108b 2.8 3 104 ± 2.9 3 101
koff (s
1) R8.5 3 101b 4.4 3 104 ± 1.1 3 106
KD (nM) 17.1 ± 0.9
c 16.0 ± 0.04
pIC50 6.8 7.7 (8.1)
See also Figures S2 and S3. SPR experiments were performed at 298 K.
Equilibrium dissociation constants (kon/koff). Potency data presented as
pIC50 (pIC50 =log10[IC50]); values in parentheses represent the potency
data for ponatinib published by ARIAD Pharmaceuticals (Gozgit et al.,
2012); data for AZD4547 were retrieved from Gavine et al. (2012).
akon is approaching the limit that can be measured by the instrument.
bKinetic rate constants are outside the limits that can bemeasured by the
instrument.
cKD was determined from dosage experiments, and binding responses at
equilibrium were fit to a 1:1 steady-state affinity. Data represent geomet-
ric mean ± SE from at least two independent experiments.
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Structures of FGFR1 and FGFR4 Inhibitor ComplexesFGFR3 (Met488) and an arginine in FGFR4 (Arg483). The tyrosine
central to the hinge in FGFR1 (Tyr563), FGFR2 (Tyr566), and
FGFR3 (Tyr557) is replaced by Cys552 in FGFR4 (Figure 3D).
Neither of these residues is involved in direct interactions with
either inhibitor, although the side chain of Tyr563 may contribute
to hydrophobic packing against the imidazopyridazine and the
pyrazole amide templates of ponatinib and AZD4547, respec-
tively. By analogy with the inferences drawn from the effects of
mutations in the hinge region on the potency and sensitivity of
ponatinib for Bcr-Abl mutants (Zhou et al., 2011), loss of an aro-
matic side chain in the hingemight be expected to reduce affinity
for ponatinib. Consistent with this hypothesis, we observed a
2-fold reduction in binding affinity (KD) for ponatinib when
comparing FGFR1 and FGFR4 (Table 2).
Given the similarities in the binding sites of FGFR4 and FGFR1,
we were unable to fully explain the differences in behavior of po-
natinib and AZD4547 toward each isoform using our structural
data alone. Thus, we sought to complement these data with so-
lution-based kinetic characterization of ponatinib and AZD4547
to the isolated kinase domains of FGFR1 and FGFR4 using SPR
(Table 2). Our kinetic analysis highlights the binding of ponatinib
to FGFR1 as exceptionally slow. With an association rate con-
stant of 2.43 104 M1 s1, it is as much as 3 orders of magnitude
slower than that of AZD4547 (kon = 2.5 3 10
7 M1 s1). Notably,
the high binding affinity of ponatinib to FGFR1 is a result of the
extraordinary stability of the FGFR1-ponatinib complex: the
dissociation rate constant for ponatinib (koff = 1.8 3 10
4 s1)
is approximately 33-fold slower than that for AZD4547 (koff =
6.0 3 103 s1). The binding of ponatinib to FGFR4 is also char-
acterized by slow kinetic rate constants, which are fairly similar
to those observed for the binding of ponatinib to FGFR1. Hence,
ponatinib shows comparable binding affinities toward FGFR1Structure 22, 1764–17(KD = 7.7 nM) and FGFR4 (KD = 16 nM), and these are in agree-
ment with the reported inhibitory potencies (Table 2; Gozgit
et al., 2012). In contrast, the binding affinities of AZD4547 for
FGFR1 and FGFR4 differ by almost 2 orders of magnitude
(FGFR1KD = 0.2 nM, FGFR4KD = 17.1 nM). The kinetic constants
for AZD4547 binding to FGFR4 are outside the limits that can be
measured by the instrument used in this study, but they clearly
indicate that a low FGFR4-AZD4547 complex stability (fast
on and off rates) is the key driver for the reduced affinity of
AZD4547 toward FGFR4 compared with FGFR1. The observed
differences in the AZD4547 binding affinities are again consistent
with the inhibitory potencies derived from the biochemical assay
(Table 2; Gavine et al., 2012). The slow kinetic rate constants
observed with ponatinib are in line with those observed for p38
with the type II inhibitor BIRB-796 (kon = 5 3 10
4 M1 s1, koff =
5.0 3 105 s1, KD = 1.0 nM) (Schreiber et al., 2006). These rate
constants were further optimized in the design of the p38 inhibitor
PF-03715455 (kon = 3 3 10
6 M1 s1, koff = 2.4 3 10
6 s1, KD =
0.001 nM) (Millan et al., 2011), suggesting that type II inhibitors of
FGFRs more potent than ponatinib can be designed.
Mapping of Somatic Mutations on the Structure
of FGFR4 Rationalizes Their Effects on Kinase Activity
and Sensitivity to Ponatinib Inhibition
Four sites of somatic mutation in the FGFR4 kinase domain have
been identified in human RMS samples (Taylor et al., 2009). Two
of these, Asn535Lys and Val550Glu, were further demonstrated
to have an activating effect on FGFR4 activity in cell-based
assays. The remaining mutations (Asn535Asp, Val550Leu,
Ala554Val, and Gly576Asp) were not experimentally character-
ized, but computational methods suggested that they would
affect FGFR4 kinase function. A number of additional somatic
mutations have been identified in breast and lung cancer sam-
ples, including Val550Met, the functional effects of which have
not been described (Davies et al., 2005; Ding et al., 2008; Green-
man et al., 2007). We sought to understand the effects these
mutationsmight have on the kinase activity of FGFR4, and sensi-
tivity to ponatinib inhibition, by mapping them onto our FGFR4-
ponatinib crystal structure (Figure 4A).
Three mutation sites (535, 550, and 554) cluster in the vicinity
of the ATP-binding cleft. Asn535 is completely conserved across
FGFR isoforms and is located in a loop region implicated as part
of the ‘‘molecular brake’’ that regulates FGFR basal activity
(Chen et al., 2007). As reported recently for FGFR2 and FGFR3
(Chen et al., 2013), mutation of this side chain to Lys or Asp
would be predicted to disrupt a network of hydrogen bonds
that otherwise restrict interlobe flexibility, thus increasing the
population of kinase in the active state. Interestingly, in our
FGFR4-ponatinib structure, the network of hydrogen bonds
that would otherwise constitute the molecular brake is partially
disengaged in the absence of any mutation. The side chain of
Asn535 is rotated with respect to the conformation observed
for the equivalent residue (Asn546) in monomer A of the
FGFR1-ponatinib structure so as to form hydrogen bonds with
the side-chain of Glu551 (Glu562 in FGFR1) and a water mole-
cule rather than to the backbone of His530 and Ile533 (His541
and Ile544, respectively, in FGFR1) (Figure 4B). In monomer B
of the FGFR1-ponatinib structure, the side chain of Asn535 has
beenmodeled in two conformations. In one of these, the network74, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1769
Figure 3. Crystal Structure of the Catalytic
Domain of FGFR1 Kinase in Complex with
AZD4547
(A) Ribbon representation of the X-ray crystal
structure of FGFR1 in complex with AZD4547
(carbon atoms in slate), labeled and colored as in
Figure 1A.
(B) 2D chemical representation of AZD4547, which
is composed of several motifs designated as the
(pyrazole amide) template, the (dimethoxyphenyl)
A ring, and the (dimethylpiperazinylphenyl) solubi-
lizing group.
(C) Active site of FGFR1 kinase in complex with
AZD4547 (carbon atoms in slate) as determined at
2.57 A˚ resolution. Fo – Fc OMIT electron density for
AZD4547, the DFGmotif and polar interactions are
represented as in Figure 1C.
(D) Overlay of the active sites of FGFR1 kinase
(light blue ribbon representation) in complex with
AZD4547 (carbon atoms in slate) and FGFR4 ki-
nase (dark green ribbon representation) in complex
with ponatinib (carbon atoms in green).
In (C) and (D), selected residues are shown as
sticks and labeled. See also Figure S1.
Structure
Structures of FGFR1 and FGFR4 Inhibitor Complexesof hydrogen bonds constituting the brake is intact (as in mono-
mer A), while in the second, an alternative network correspond-
ing to a disengaged brake as observed in the FGFR4-ponatinib
structure is evident.
The gatekeeper residue (Val550) is also conserved across all
FGFR isoforms and lies at the N terminus of the hinge region.
Gatekeeper mutations in other tyrosine kinases have been
shown to stabilize the hydrophobic spine (Azam et al., 2008),
thus leading to enhanced kinase activity through stabilization
of the active state. A similar effect is likely for the FGFR4 gate-
keeper mutations where, for example, both Val550Leu and
Val550Met increase the size of the gatekeeper residue, allowing
improved packing. As expected, binding of ponatinib to FGFR4
and FGFR1 disrupts the hydrophobic spine through displace-
ment of the Phe side chain to the DFG-out conformation (Fig-
ure 4C, left). In contrast, the FGFR1-AZD4547 structure shows
an intact hydrophobic spine (Figure 4C, right). Mutation of
Val550 to amino acids with bulkier side chains such as Met or
Leu would be predicted to alter the sensitivity of FGFR4 to inhib-
itors, such as ponatinib and AZD4547, that access the pocket
beyond this residue by a mechanism of steric hindrance (Fig-
ure 4D). This has been observed for the FGFR2 gatekeeper mu-
tation Val565Ile, which confers resistance to ponatinib (Byron
et al., 2013).
DISCUSSION
The X-ray crystal structures of the kinase domains of FGFR1 and
FGFR4 bound to the pan-FGFR TKI ponatinib presented here
show that both FGFR isoforms bind the inhibitor in a type II,1770 Structure 22, 1764–1774, December 2, 2014 ª2014 Elsevier Ltd All rights reservedDFG-out binding mode, similar to that
observed for its originally reported target
Bcr-Abl. This prompts the question of
whether the apparently refractory nature
of FGFRs toward adoption of the DFG-out conformation lies at the level of the protein itself or is more
a function of an exacting requirement for specific chemical in-
teraction motifs in the inhibitor. The ponatinib-binding mode
contrasts with that of the archetypal type I pose adopted by
AZD4547, whose structure we have determined in complex
with FGFR1 and present here. Our data comparing the distinct
binding modes of these two inhibitors reveal that the potencies
exhibited for the two FGFR isoforms cannot be fully explained
by structural comparison alone. Our kinetic characterization of
ponatinib and AZD4547 binding to FGFR1 and FGFR4 reveals
dramatic differences in the association and dissociation rates
between the two TKIs; ponatinib binds and dissociates up to
100-foldmore slowly than AZD4547. These slow binding kinetics
suggest the existence of a high-energy barrier to the attainment
of the DFG-out protein conformation and/or may indicate a
requirement for ponatinib to rearrange to a less energetically
favorable conformation in order to allow binding to the predom-
inant kinase conformation in solution. Further detailed mecha-
nistic investigations, together with insights into the underlying
protein conformational dynamics derived from nuclear magnetic
resonance relaxation studies, will be required to develop a com-
plete picture of the factors governing the DFG-flip in FGFRs.
Work to further elucidate the role of dynamics is ongoing in our
laboratory and will be described elsewhere.
Mechanistic characterization of disease-associatedmutations
in FGFRs has highlighted the importance of the molecular brake
and the role of a key conserved asparagine residue (Asn535 in
FGFR4) in maintaining the kinase in the inactive state. A recent
report from Byron and coworkers suggests that mutation of
this residue may also alter FGFR2 sensitivity to inhibition by
Figure 4. Structural Modeling of Somatic
FGFR4 Mutations
(A) Codons 535, 550, 554, and 576 (red) mapped
onto the structure of FGFR4 kinase in complex with
ponatinib (colored as in Figure 1).
(B) Close-up view of the intramolecular interactions
of Asn535 and neighboring residues in the FGFR4-
ponatinib (left) and FGFR1-ponatinib (right) com-
plexes.
(C) Close-up view of the disassembled hydro-
phobic spine (carbon atoms in gray and van
der Waals surface shown) in the FGFR4-ponati-
nib complex (top), with the DFG phenylalanine
(carbon atoms in orange and van der Waals
surface shown) flipped outward to form an
extended cavity for ponatinib binding. Close-
up view of the intact hydrophobic spine in
the FGFR1-AZD4547 complex (bottom), with the
DFG phenylalanine as a key component of in-
terlobe connectivity.
(D) Close-up view of FGFR4 gatekeeper residue
(Val550, shown as atomic spheres) interaction with
ponatinib (carbon atoms in green and van der
Waals surface shown) (left). Close-up view of
predicted steric clash between bulky gatekeeper
mutant (Met550, shown as atomic spheres) with
ponatinib (right).
See also Figure S1.
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Structures of FGFR1 and FGFR4 Inhibitor Complexesdifferent classes of TKIs (Byron et al., 2013). The Asn550Lys mu-
tation in FGFR2 conferred resistance to the type I inhibitors
PD173074 and dovitinib but not to the type II TKI ponatinib.
Our structures appear consistent with these data in that we
observe an engaged brake in the structure of the FGFR1-
AZD4547 complex, a predominantly engaged brake in the struc-
ture of the FGFR1-ponatinib complex, and a disengaged brake in
the structure of FGFR4 in complex with ponatinib. Although by
no means conclusive, the observed differences in the degree
of molecular brake engagement among our FGFR1 and FGFR4
structures suggest the potential for greater flexibility in FGFR4,
such that in solution, the FGFR4 kinase domain may sample a
wider range of conformations, occupying an active-like confor-
mation more often than FGFR1. Such a difference in dynamic
behavior is consistent with our kinetic data, which show a
decrease in stability for the complex of AZD4547 with FGFR4
compared with FGFR1. It would also be consistent with the
reduced propensity of FGFR4 to crystallize compared with
FGFR1, and the lower Tm for the FGFR4 kinase domain in the
apo state (Table S1). Finally, increased conformational flexibility
in FGFR4 may contribute to the potency drop-off observed for
AZD4547 and other type I FGFR inhibitors, which may bind pref-
erentially to a conformation in which the molecular brake is
engaged. Further work will be required to fully elucidate these
differences in conformational dynamics and understand their
impact on inhibitor binding and isoform selectivity.
The demonstration that FGFR1 and FGFR4 can adopt the
inactive DFG-out conformation opens new avenues for the
design of novel FGFR type II kinase inhibitors with differing selec-Structure 22, 1764–17tivity and kinetic profiles. Hybrid design approaches in which
type I inhibitor templates are linked to type II inhibitor A ring
moieties known to bind in the DFG-out pocket have proved suc-
cessful in several kinase systems, notably in the development of
second- and third-generation Bcr-Abl inhibitors (Liu and Gray,
2006) and p38 kinase inhibitors (Millan et al., 2011). This
approach is now available for the design of next generation
FGFR kinase inhibitors with longer residence times, which may
provide a higher barrier to the development of chemoresistance.
Availability of the FGFR4 crystal structure has enabled us to
make a detailed comparison of the active sites of FGFR1 and
FGFR4. This has highlighted a key difference in the hinge region;
Tyr563 in FGFR1 (also conserved in FGFR2 and FGFR3) is
Cys552 in FGFR4. A recent paper by Zhou and coworkers pre-
sents the development of pan-FGFR inhibitors that covalently
target the conserved Cys in the P loop (Zhou et al., 2010). Appli-
cation of a similar approach to develop covalent inhibitors target-
ing Cys552 could be envisaged as a strategy for the design of
FGFR4-selective inhibitors. Combined targeting of Cys552 and
the DFG-out hydrophobic pocket could provide a means to the
creation of inhibitors which are both potent and selective against
FGFR4.
EXPERIMENTAL PROCEDURES
Additional details are provided in Supplemental Experimental Procedures.
Compound Synthesis
Ponatinib was purchased from Selleckchem. AZD4547 was synthesized as
previously described (Gavine et al., 2012).74, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1771
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Structures of FGFR1 and FGFR4 Inhibitor ComplexesKinase Inhibition Assay
The inhibitory activity of ponatinib against FGFR1 and FGFR4 kinases was
determined with a Caliper off-chip incubationmobility shift assay as previously
described (Norman et al., 2012a).
Thermal Shift Analysis
Thermal melting experiments using the Thermofluor technique were used to
identify compounds that stabilized the FGFR4 kinase domain (Holdgate,
2007). Full details are provided in Supplemental Experimental Procedures.
Protein Expression and Purification
Human FGFR4 consisting of residues Ala447-Glu753 with an engineered
N-terminal TEV protease-cleavable 6His tag and a Cys477Ala mutation was
expressed in E. coli BL21 (DE3) GOLD. Coexpression with untagged PTP1B
provided nonphosphorylated FGFR4. FGFR4 was purified by immobilized
metal affinity chromatography (IMAC), TEV protease cleavage to remove the
6His tag, subtractive IMAC, and size exclusion chromatography (SEC). Human
FGFR1 consisting of residues Ala458-Glu765 with an engineered TEV prote-
ase-cleavable N-terminal 6His tag and mutations Cys488Ala and Cys584Ser
(Mohammadi et al., 1996) was expressed and purified as previously described
(Norman et al., 2012a) with minor modifications. The 6His tag was retained on
proteins destined for SPR experiments, and for FGFR4, an additional ion
exchange stepwas used prior to the final SEC. Full details are provided in Sup-
plemental Experimental Procedures.
Crystallization
FGFR4-Ponatinib Complex
GS-FGFR4(Ala447-Glu753)[Cys477Ala] in SEC buffer at 12 mg/mL was mixed
with a 100 mM ponatinib stock solution in DMSO to give a final concentration
of 1 mM ponatinib, 1%DMSO. Complex formation was allowed to proceed for
3 hours at 277 K. The sample was clarified by centrifugation (16,000 3 g,
277 K, 5 min), and crystals were grown at 277 K by sitting drop vapor diffusion
using a 1:1 ratio of FGFR4-ponatinib complex to precipitant, consisting of
0.1 M PCTP (pH 4.5) (0.04 M sodium propionate, 0.02 M sodium cacodylate,
0.04 M bis-tris propane), 0.1 M (NH4)2SO4, and 15% PEG3350, to give a 400
nL drop. Crystals grew as stacked plates, appearing within 3 weeks. Crystals
were passed quickly through precipitant supplemented with 20% glycerol and
then flash cooled in a gaseous nitrogen stream at 100 K prior to data collection.
FGFR1 complexes were crystallized essentially as described (Norman et al.,
2012a) with minor modifications, detailed in Supplemental Experimental
Procedures.
X-Ray Diffraction Data Collection and Processing
FGFR4-Ponatinib Complex
X-ray diffraction data were collected from three different crystals at the
European Synchrotron Radiation Facility (ESRF) and Diamond synchrotrons
(Table 1). The highest resolution data from crystal 3 were compromised by
poor spot shapes and ice rings and were therefore combined with the lower
resolution data from crystals 1 and 2 in order to improve the data complete-
ness and reduce the discontinuities in the electron density maps arising
from systematic incompleteness in the crystal 3 data. Data were processed
using XDS (Kabsch, 2010) as implemented within XIA2 (Winter et al., 2013)
(Diamond data) or EDNA (Incardona et al., 2009) (ESRF data), scaled and
merged using SCALA (Evans, 2006), and further processed using programs
from the CCP4 suite (Winn et al., 2011).
FGFR1 Complexes
X-ray diffraction data were collected on a rotating anode generator (Rigaku
FRE) equipped with a Saturn944 CCD detector. Data were integrated and
scaled with d*trek (Pflugrath, 1999) or XDS and Aimless as implemented within
autoPROC (Vonrhein et al., 2011). Data were further processed using pro-
grams from the CCP4 suite (Winn et al., 2011).
Structure Solution, Refinement, and Validation
Structures were solved by molecular replacement using internal FGFR1 struc-
tures as search models. Full details are provided in Supplemental Experi-
mental Procedures. Manual model completion in Coot (Emsley et al., 2010)
was interspersed with rounds of maximum-likelihood refinement in Buster
(Bricogne et al., 2011) and REFMAC5 (Murshudov et al., 2011), applying TLS1772 Structure 22, 1764–1774, December 2, 2014 ª2014 Elsevier Ltdparameters, and noncrystallographic symmetry restraints where appropriate.
Stereochemical restraints for ponatinib and AZD4547 were generated using
Corina (Sadowski et al., 1994). Quality checks on the protein structures were
carried out using the validation tools in Coot (Emsley et al., 2010) and MolPro-
bity (Chen et al., 2010b), while compound stereochemistries were checked
against the Cambridge Structural Database (Allen, 2002) using Mogul (Bruno
et al., 2004). Final structures have been deposited in the PDB, with accession
numbers given in Table 1.
All structural figures were prepared using PyMOL (Schro¨dinger). Rmsd
values between structures were calculated using the SSM algorithm (Krissinel
and Henrick, 2004) as implemented within CCP4MG (McNicholas et al., 2011).
SPR
SPR experiments were performed using the Biacore 3000 and Biacore T200
biosensors (GE Healthcare). Nitriloacetic acid (NTA) sensor chips and series
S NTA sensor chips (GE Healthcare) were used. All experiments were done us-
ing PBS (pH 7.4), 50 mMEDTA, 0.05% (v/v) surfactant P20, and 1% (v/v) DMSO
as running buffer. Compounds as DMSO stocks were diluted in DMSO to con-
centrations 100-fold higher than the final assay concentration. Finally, they
were diluted 1:100 (v/v) in running buffer without DMSO, to achieve the target
concentration resulting in a final DMSO concentration of 1% (v/v). Further
experimental details are provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The coordinates and structure factors for all structures described here have
been deposited in the PDB under accession numbers 4V01, 4V04, 4V05,
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